Clinical risk management in Dutch community pharmacies: The case of drug-drug interactions

Drug Safety

Volumn 29, Issue 8, 2006, Pages 723-732

  Buurma, Henk ^a,b   De Smet, Peter A G M ^c,d   Egberts, Antoine C G ^b  

^a SIR Institute for Pharmacy Practice and Policy   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Scientific Institute of Dutch Pharmacists (WINAp)   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN ANTAGONIST; ANTIINFECTIVE AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CORTICOSTEROID DERIVATIVE; COUMARIN ANTICOAGULANT; DIGOXIN; DILTIAZEM; DIURETIC AGENT; INSULIN; IRON; LEVOTHYROXINE; METAL ION; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; ORAL CONTRACEPTIVE AGENT; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; RENIN INHIBITOR; SALICYLIC ACID DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; VERAPAMIL;

ADOLESCENT; ADULT; AGED; ANTICOAGULATION; ARTICLE; CHILD; COMPLEX FORMATION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CLASSIFICATION; DRUG POTENTIATION; DRUG RESEARCH; FEMALE; HUMAN; INFANT; INTERPERSONAL COMMUNICATION; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEDICAL RECORD; NETHERLANDS; NEWBORN; OUTCOME ASSESSMENT; PHARMACIST; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RISK MANAGEMENT;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR AGENTS; CHILD; CHILD, PRESCHOOL; COMMUNITY PHARMACY SERVICES; CONTRACEPTIVES, ORAL; DRUG INTERACTIONS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MEDICAL ORDER ENTRY SYSTEMS; MIDDLE AGED; NETHERLANDS; RISK MANAGEMENT;

EID: 33746828947     PISSN: 01145916     EISSN: 01145916     Source Type: Journal    
DOI: 10.2165/00002018-200629080-00009     Document Type: Article

References (36)

1. Misson JC. A review of clinical risk management. J Qual Clin Pract 2001; 21 (4): 131-4
2. Madar J. Clinical risk management in newborn and neonatal resuscitation. Semin Fetal Neonatal Med 2005; 10 (1): 45-61
3. Guideline on risk management systems for medicinal products for human use. London: European Medicines Evaluation Agency, 2005 Sep 6
4. Buurma H, de Smet PA, van den Hoff OP, et al. Nature, frequency and determinants of prescription modifications in Dutch community pharmacies. Br J Clin Pharmacol 2001; 52 (1): 85-91
5. Sandars J, Esmail A. The frequency and nature of medical error in primary care: understanding the diversity across studies. Fam Pract 2003; 20 (3): 231-6
6. Kohn LT, Corrigan CJ, Donaldson MS, editors. To err is human: building a safer health system. Washington, DC: National Academy Press, 1999
7. Westerlund LT, Marklund BR, Handl WH, et al. Nonprescription drug-related problems and pharmacy interventions. Ann Pharmacother 2001; 35 (11): 1343-9
8. Boyko Jr WL, Yurkowski PJ, Ivey MF, et al. Pharmacist influence on economic and morbidity outcomes in a tertiary care teaching hospital. Am J Health Syst Pharm 1997; 54 (14): 1591-5
9. Bouvy ML, Buurma H, Egberts TC. Laxative prescribing in relation to opioid use and the influence of pharmacy-based intervention. J Clin Pharm Ther 2002; 27 (2): 107-10
10. Beney J, Bero LA, Bond C. Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes. Cochrane Database Syst Rev 2000; (3): CD000336
11. Singhal PK, Raisch DW, Gupchup GV. The impact of pharmaceutical services in community and ambulatory care settings: evidence and recommendations for future research. Ann Pharmacother 1999; 33 (12): 1336-55
12. Tully MP, Seston EM. Impact of pharmacists providing a prescription review and monitoring service in ambulatory care or community practice. Ann Pharmacother 2000; 34 (11): 1320-31
13. Buurma H, De Smet PA, Leufkens HG, et al. Evaluation of the clinical value of pharmacists' modifications of prescription errors. Br J Clin Pharmacol 2004; 58 (5): 503-11
14. Jankel CA, Fitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf 1993; 9 (1): 51-9
15. Raschetti R, Morgutti M, Menniti-Ippolito F, et al. Suspected adverse drug events requiring emergency department visits or hospital admissions. Eur J Clin Pharmacol 1999; 54 (12): 959-63
16. Bouvy ML, Heerdink ER, Hoes AW, et al. Effects of NSAIDs on the incidence of hospitalisations for renal dysfunction in users of ACE inhibitors. Drug Saf 2003; 26 (13): 983-9
17. Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003; 289 (13): 1652-8
18. Huang SM, Lesko LJ. Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned? J Clin Pharmacol 2004; 44 (6): 559-69
19. Van Roon EN, Flikweert S, le Comte M, et al. Clinical relevance of drug-drug interactions: a structured assessment procedure. Drug Saf 2005; 28 (12): 1131-9
20. Klungel OH, de Boer A, Paes AH, et al. Agreement between self-reported antihypertensive drug use and pharmacy records in a population-based study in The Netherlands. Pharm World Sci 1999; 21 (5): 217-20
21. Monster TB, Janssen WM, de Jong PE, et al. Pharmacy data in epidemiological studies: an easy to obtain and reliable tool. Pharmacoepidemiol Drug Saf 2002; 11 (5): 379-84
22. van Mil JW, Dudok van Heel MC, Boersma M, et al. Interventions and documentation for drug-related problems in Dutch community pharmacies. Am J Health Syst Pharm 2001; 58 (15): 1428-31
23. Knapp KK, Katzman H, Hambright JS, et al. Community pharmacist interventions in a capitated pharmacy benefit contract. Am J Health Syst Pharm 1998; 55 (11): 1141-5
24. Halkin H, Katzir I, Kurman I, et al. Preventing drug interactions by online prescription screening in community pharmacies and medical practices. Clin Pharmacol Ther 2001; 69 (4): 260-5
25. Merlo J, Liedholm H, Lindblad U, et al. Prescriptions with potential drug interactions dispensed at Swedish pharmacies in January 1999: cross sectional study. BMJ 2001; 323 (7310): 427-8
26. Bjerrum L, Andersen M, Petersen G, et al. Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 2003; 21 (3): 153-8
27. Peng CC, Glassman PA, Marks IR, et al. Retrospective drug utilization review: incidence of clinically relevant potential drug-drug interactions in a large ambulatory population. J Manag Care Pharm 2003; 9 (6): 513-22
28. Chen YF, Avery AJ, Neil KE, et al. Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. Drug Saf 2005; 28 (1): 67-80
29. Bergk V, Gasse C, Rothenbacher D, et al. Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther 2004; 76 (1): 85-96
30. Guedon-Moreau L, Ducrocq D, Duc MF, et al. Absolute contra-indications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999. Eur J Clin Pharmacol 2003; 59 (8-9): 689-95
31. Viktil KK, Blix HS, Reikvam A, et al. Comparison of drug-related problems in different patient groups. Ann Pharmacother 2004; 38 (6): 942-8
32. Roughead EE, Barratt JD, Gilbert AL. Medication-related problems commonly occurring in an Australian community setting. Pharmacoepidemiol Drug Saf 2004; 13 (2): 83-7
33. Weingart SN, Toth M, Sands DZ, et al. Physicians' decisions to override computerized drug alerts in primary care. Arch Intern Med 2003; 163 (21): 2625-31
34. De Smet PA. Health risks of herbal remedies: an update. Clin Pharmacol Ther 2004; 76 (1): 1-17
35. Abarca J, Malone DC, Armstrong EP, et al. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc (Wash DC) 2004; 44 (2): 136-41
36. Becker ML, Kallewaard M, Caspers PW, et al. Potential determinants of drug-drug interaction associated dispensing in community pharmacies. Drug Saf 2005; 28 (5): 371-8